The U.S. Food and Drug Administration announced on Monday, November 9, 2026, that manufacturers of all GLP-1 receptor agonist medications must add new warnings to their product labels regarding a rare eye condition associated with sudden, permanent vision loss. The regulatory order applies across the entire class of blockbuster weight-loss and diabetes treatments, including Novo Nordisk’s Ozempic and Wegovy as well as Eli Lilly’s Mounjaro and Zepbound, according to the U.S. Food and Drug Administration.

The updates will be placed in the Warnings and Precautions section of the prescribing information, alerting clinicians and millions of American patients to a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION.

While regulators emphasize that the condition remains rare and that data do not prove the medications directly cause the disorder, the mandate ensures that patients know to seek immediate medical evaluation if they experience sudden changes in eyesight.

Understanding NAION and Which Medications Are Affected

NAION is an eye condition caused by reduced or blocked blood flow to the front portion of the optic nerve, known as the optic disc, which transmits visual signals from the eye to the brain. As reported by NBC News, NAION is the second most common optic nerve disease in the United States, occurring in between 2 and 10 out of every 100,000 adults over the age of 50, based on figures from the American Academy of Ophthalmology. The resulting vision loss is typically acute and painless, and there is currently no known treatment to reverse the damage once it occurs.

The agency’s requirement covers a dozen injectable and oral GLP-1 drugs approved since 2005, according to Reuters. This includes semaglutide products like Ozempic (approved in 2017) and Wegovy, tirzepatide products like Mounjaro and Zepbound (approved in 2023), and Novo Nordisk’s oral diabetes medication Rybelsus, alongside older drugs in the class.

According to the U.S. Food and Drug Administration, cases of NAION have been reported across all currently marketed GLP-1 medications, which work by mimicking a natural intestinal hormone that lowers blood sugar levels and regulates appetite.

These medications already carry labeling warnings for other potential health complications, including pancreatitis, gallbladder problems, and acute kidney injury, as well as a boxed warning regarding a possible risk of thyroid tumors.

How Clinical Data and Patient Reports Led to the Warning

Federal scientists began investigating the issue following the publication of a 2024 study in JAMA Ophthalmology, which found that diabetes patients prescribed semaglutide were four times as likely to develop NAION compared to peers taking other medications. Subsequent international scrutiny added momentum to the inquiry. As reported by CNN, a large 2025 study tracking nearly 175,000 diabetic patients treated with semaglutide alongside an equal number taking non-GLP-1 medications found that the risk of developing NAION more than doubled after two years of treatment.

Last year, the European Medicines Agency’s safety committee concluded that Wegovy and Ozempic may cause NAION in very rare cases affecting up to 1 in 10,000 patients taking semaglutide for at least a year, and Danish authorities granted compensation to four patients who experienced vision loss after using Novo Nordisk's GLP-1 drugs.

To assess the safety signal, FDA researchers reviewed post-marketing adverse event reports, animal data, and 126 randomized, controlled clinical trials. How the resulting frequency is described varies slightly across medical and news reports due to different statistical denominators. According to an FDA trial analysis summarized by MedPage Today, reviewers identified 15 probable NAION events among 134,253 patients—10 in patients treated with GLP-1 drugs and five in placebo recipients—translating to an incidence rate of 6.4 cases per 100,000 person-years for GLP-1 users versus 3.8 per 100,000 person-years for those on a placebo or non-GLP-1 medication.

Meanwhile, CBS News reports that the problem occurred in roughly 6 of every 100,000 patients who took a GLP-1 medication for at least one year, compared to fewer than 4 per 100,000 in comparator groups.

Despite the statistical link, investigators have not been able to identify a biological mechanism explaining how GLP-1 receptor agonists might trigger reduced blood flow to the optic nerve. Evaluating the relationship is complicated because the underlying risk factors for NAION—such as Type 2 diabetes, high blood pressure, sleep apnea, kidney disease, anemia, and smoking—heavily overlap with the health profiles of patients prescribed GLP-1 medications.

While some media summaries describe the medications as being directly linked to blindness, the U.S. Food and Drug Administration frames the update strictly as a potential association rather than proof of cause and effect. Drugmakers echoed that distinction on Monday.

Novo Nordisk stated to CBS News that it remains confident in the benefit-risk profile of its products and believes the data do not establish a causal relationship, while Eli Lilly noted that patient safety is its top priority and pointed out that the agency's communication applies to the broad drug class without referencing findings specific to Lilly medicines.

Dr. Joseph Rizzo, a neuro-ophthalmologist at Massachusetts Eye and Ear who co-authored the 2024 paper and collaborated with the FDA on reviewing the data, told CBS News that he was not surprised by the agency's decision. Even so, Rizzo emphasized that he does not discourage patients from using the drugs, noting that the medications have been "profoundly beneficial to a large number of people."

What Patients Should Know and Watch For

For the millions of Americans relying on GLP-1 therapies for blood sugar management, cardiovascular protection, or weight reduction, medical experts and regulators advise vigilance rather than panic.

Because NAION strikes without pain, recognizing visual changes early is critical for proper clinical assessment.

What symptoms should prompt urgent medical attention?

Patients and caregivers should contact a healthcare professional right away if they experience sudden, painless vision loss or decreased vision in one eye—a change that many individuals first notice upon waking up in the morning. Other warning signs include blind spots or missing portions of the visual field, tunnel vision, distortion of colors, and blurry or hazy areas that reduce central sharpness.

Should patients stop taking their GLP-1 medication to prevent eye problems?

Health authorities do not advise patients to stop taking prescribed GLP-1 medications on their own. For most individuals, the metabolic and cardiovascular benefits of treatment remain substantial. However, the updated FDA labeling directs clinicians to promptly refer patients to an ophthalmologist if NAION is suspected.

If a patient is diagnosed with NAION, doctors and patients are advised to discuss whether to discontinue the medication, as experiencing the condition in one eye increases the risk of it occurring in the other eye.

Does this warning mean GLP-1 drugs definitely cause blindness?

No. The FDA safety communication highlights a potential increased risk based on observational studies and a small number of events in clinical trials, but it does not establish that the medications directly cause the optic nerve damage. Patients with underlying conditions like diabetes, hypertension, or sleep apnea are encouraged to maintain regular eye exams and discuss their individual risk factors with their prescribing physician.

Sources